Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2019 2
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Are we facing a cure in lung cancer?-KEYNOTE-001 insights.
Cohen AY, Kian W, Roisman LC, Levitas D, Peled N, Dudnik Y. Cohen AY, et al. Ann Transl Med. 2019 Sep;7(Suppl 6):S215. doi: 10.21037/atm.2019.08.87. Ann Transl Med. 2019. PMID: 31656794 Free PMC article. No abstract available.
Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors.
Yakobson A, Rouvinov K, Cohen AY, Goldstein I, Abu Saleh O, Solomon A, Dudnik Y, Shalata W. Yakobson A, et al. Among authors: cohen ay. J Pers Med. 2023 Aug 30;13(9):1340. doi: 10.3390/jpm13091340. J Pers Med. 2023. PMID: 37763109 Free PMC article.
Unexpected Adverse Events of Immune Checkpoint Inhibitors.
Shalata W, Yakobson A, Cohen AY, Goldstein I, Saleh OA, Dudnik Y, Rouvinov K. Shalata W, et al. Among authors: cohen ay. Life (Basel). 2023 Jul 29;13(8):1657. doi: 10.3390/life13081657. Life (Basel). 2023. PMID: 37629514 Free PMC article.
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs).
Raphael A, Onn A, Holtzman L, Dudnik J, Urban D, Kian W, Cohen AY, Moskovitz M, Zer A, Bar J, Rabinovich NM, Grynberg S, Oedegaard C, Agbarya A, Peled N, Shochat T, Dudnik E. Raphael A, et al. Among authors: cohen ay. Front Oncol. 2022 May 13;12:874712. doi: 10.3389/fonc.2022.874712. eCollection 2022. Front Oncol. 2022. PMID: 35646707 Free PMC article.
Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E, Bar J, Peled N, Bshara E, Kuznetsov T, Cohen AY, Shochat T, Nechushtan H, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadar N, Urban D, Mishaeli M, Rabinovich NM, Brenner R, Zer A, Rotem O, Roisman LC, Wollner M; Israel Lung Cancer Group. Dudnik E, et al. Clin Lung Cancer. 2019 Jul;20(4):278-286.e1. doi: 10.1016/j.cllc.2019.03.007. Epub 2019 Apr 5. Clin Lung Cancer. 2019. PMID: 31060855